Ingredient or product comparison
GHK-Cu Versus the Proven Standards of Care
The fairest way to calibrate GHK-Cu’s evidence is to set it beside the two agents that actually cleared the regulatory bar for androgenetic alopecia. The contrast is not meant to disparage GHK-Cu; it is meant to show what “clinical research indicates” looks li
This source-based comparison does not add ratings or recommend a winner.
- The fairest way to calibrate GHK-Cu’s evidence is to set it beside the two agents that actually cleared the regulatory bar for androgenetic alopecia. The contrast is not meant to disparage GHK-Cu; it is meant to show what “clinical research indicates” looks like when the answer is genuinely established.
- Minoxidil is FDA-approved as a topical treatment (2% and 5%) for pattern hair loss in men and women. Its mechanism is understood as potassium-channel opening and vasodilation, with prolongation of the anagen growth phase; decades of controlled trials support a real, if modest, benefit in a substantial fraction of users.8 Finasteride is an oral 5-alpha-reductase inhibitor approved for male pattern hair loss; by lowering DHT it directly targets the hormonal driver of miniaturization, and large trials document meaningful maintenance and partial regrowth over time.78 Both drugs have known limitations and side-effect profiles, and neither “cures” the condition — benefits generally require continued use. But both rest on a foundation of pivotal, replicated human trials that GHK-Cu simply does not have for this indication.
- Regulatory status for AGA
- FDA-approved (topical)
- FDA-approved (oral, men)
- Cosmetic ingredient; not approved for hair loss
- Primary mechanism
- K⁺ channel opening, vasodilation, anagen prolongation8
- 5-α-reductase inhibition → lower DHT7
- Dermal papilla support, VEGF/angiogenesis, anti-inflammatory (mechanistic)12
- Highest evidence tier
- Multiple RCTs
- In vitro / ex vivo; no robust monotherapy RCT
- Human hair-count data
- Extensive
- Sparse, indirect, often combination-based
- Targets DHT pathway?
- No (downstream)
- Yes (directly)
- Not convincingly in humans
- Honest positioning
- Proven, modest, ongoing use
- Proven, hormonal, ongoing use
- Plausible adjunct; unproven as a standalone therapy
- The comparison clarifies GHK-Cu’s realistic place. It is not a competitor to minoxidil and finasteride on the evidence; it is, at best, a mechanistically reasonable adjunct whose independent contribution has not been quantified in controlled human trials. A researcher or clinician who understands this will neither dismiss the peptide outright nor promote it as a proven therapy — both errors ignore where the data actually sit.